Regulatory, Strategies & Submissions

Overcome the obstacles to get products to market faster and smarter.

  • Biosimilars in the time of COVID-19 and beyond

    Biosimilars in the time of COVID-19 and beyond

    Introduction The recent COVID-19 pandemic has triggered a race for pharmaceutical companies to repurpose their commercialized drugs approved for other clinical indications to treat patients...

    Learn More
  • Critical considerations for re-starting clinical trials in countries recovering after the COVID-19 pandemic

    Critical considerations for re-starting clinical trials in countries recovering after the COVID-19 pandemic

    The COVID-19 pandemic led to a variety of risk-based adjustments to clinical trial conduct. Mitigation measures had to be taken based on a risk assessment by sponsors and investigators in which...

    Learn More
  • COVID19 Risk mitigation Services Factsheet

    COVID19 Risk mitigation Services Factsheet

    Read More
  • Parexel Regulatory & Access Overview Brochure

    Parexel Regulatory & Access Overview Brochure

    Read More
  • ×

    Let's start a conversation...

    First Name
    Last Name
    Job Title
    Company Name
    Country
    Therapeutic Area Interest - optional
    Tell us how we can help
    Thank you! We'll be in touch soon.
    Error - something went wrong!
  • Commercial and Regulatory Strategy Considerations for Biotech

    Commercial and Regulatory Strategy Considerations for Biotech

    Many critical and innovative new therapies today, including those for rare and untreated diseases, are in the biotech pipeline. In fact, today biotech represents more than 80 percent of the...

    Learn More
  • Commercial and regulatory strategy considerations for biotech

    Commercial and regulatory strategy considerations for biotech

    In this blog, Parexel regulatory and strategy experts tackle the question of how we can ensure that worthy innovations in the biotech pipeline make it to patients sooner.

    Learn More
  • RWE in an evolving regulatory landscape: Using real-world evidence to support novel product development pathways

    RWE in an evolving regulatory landscape: Using real-world evidence to support novel product development pathways

    In this on-demand webinar, Parexel experts discuss the growing interest in RWE from both regulators and payors and the advantages of using real-world data (RWD) to streamline the research process.

    Learn More
  • What you need to know about FDA’s NEW draft Drug Master Files Guidance for Industry

    What you need to know about FDA’s NEW draft Drug Master Files Guidance for Industry

    Drug Master Files (DMFs) may be submitted to the FDA to provide confidential and often proprietary information regarding facilities, processes, or components used in the manufacturing,...

    Learn More
  • Regulatory Update: Patient Engagement in Drug Development

    Regulatory Update: Patient Engagement in Drug Development

    This month, the FDA released a draft of its second patient-focused drug development (PFDD) guidance document, detailing best practices for understanding patient experiences and the related...

    Learn More
  • Cell and Gene Therapy & Tissue Engineering

    Cell and Gene Therapy & Tissue Engineering

    Read More
  • A Perspective on GMPS Cellular Therapy

    A Perspective on GMPS Cellular Therapy

    Read More
  • 3 ways to reap the benefits of adaptive trials

    3 ways to reap the benefits of adaptive trials

    Read More
  • Strengthen Your Product Value Story One Phase At A Time

    Strengthen Your Product Value Story One Phase At A Time

    Find out how to plan evidence generation for your value story!

    Read More
  • Agency Readiness – Bob Iser2:48

    Agency Readiness – Bob Iser

    Watch Video
  • ×

    Let's start a conversation...

    First Name
    Last Name
    Job Title
    Company Name
    Country
    Therapeutic Area Interest - optional
    Tell us how we can help
    Thank you! We'll be in touch soon.
    Error - something went wrong!
  • Accelerated Pathways – Alberto Grignolo2:55

    Accelerated Pathways – Alberto Grignolo

    Watch Video
  • Strategies for Working with Global Regulatory Agencies

    Strategies for Working with Global Regulatory Agencies

    Early engagement with regulatory authorities can help boost regulatory success rates and also help shorten clinical development timelines.

    Read More
  • Phase III Trial Failures: Costly But Preventable

    Phase III Trial Failures: Costly But Preventable

    This article examines reasons for the high failure rate of Phase III studies and innovative approaches companies can take to mitigate risk.

    Read More
  • Three Steps for Filling Real-World Evidence Gaps

    Three Steps for Filling Real-World Evidence Gaps

    Create a strong RWE evidence strategy that addresses three critical factors: product differentiation, clinical outcomes in the real world and evidence gaps that may crop up suddenly.

    Read More
  • loading
    Loading More...